Article

[The prevalence and clinical characteristics of heart failure in a population sample of Calabria]

Authors:
  • Interventional Cardiology, Annunziata Civil Hospital, Cosenza
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

Two-hundred and fourteen patients with congestive heart failure were identified over a six-month period in the general practice of 29 GPs covering an adult population of 29,959 subjects residing in the region of Calabria, in southern Italy, with an overall prevalence of 7 per 1000. Males represented 52% of the cases and females 48%, with a median age of 75 years. On average, the condition was first diagnosed 41 months before the present examination. Patients generally had a high body mass index (28 kg/m2). Patients were classified as follows in the NYHA classification: 9.4% in class I, 45.3% in class II, 39.2% in class III, 6.1% in class IV. Hypertension, either alone or associated with ischemic heart disease (totally about 75% of cases), was the most common etiology, while COPD was the most commonly associated chronic condition. Clinical symptoms and signs were used to classify patients in a simplified version of the Boston score which was reported in 48% of cases as definite, 12% as possible, 6% as improbable and 34% as absent. A specific treatment was already ongoing in 97% of patients. The most commonly administered drugs were diuretics (83%), ACE-inhibitors (77%), and digitalis (67%). This three-drug combination (alone or with other drugs) covered 46% of patients. A comparison of four predefined typologies of treatment against the Boston score suggested that at least part of the outcome in classifying patients using this procedure was due to pathomorphosis of the syndrome induced by early pharmacological treatment.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

Article
Full-text available
Objective To compare the economic consequences of treating chronic heart failure (CHF) with high versus low dosage lisinopril. Design A cost-effectiveness analysis compared cost and effects of lisinopril 32.5–35 versus 2.5–5 mg/die in the perspective of the Italian National Health Service (NHS). Effects and resources absorption were derived from the ATLAS results. Pharmacological costs were quantified according to the Italian market price of the drug; hospitalisation costs were quantified on the basis of DRG tariffs. Effects are expressed as reduction of cardiovascular morbidity and mortality and life-years saved (LYS). For both costs and effects a 5% annual discount was applied. Setting CHF patients in an hypothetical Italian setting, according to the ATLAS design. Patients and participants More than 3000 patients with NYHA classes II to IV, CHF and left ventricular ejection fractions equal or less than 0.30. Main outcome measures and results Clinical effects of treating 1000 patients for 3.58 years with high versus low dosage lisinopril would correspond to a saving of € 99.300. The therapy with high dosage of lisinopril dominates the alternative with the low dosage of the drug. Conclusions Treating CHF patients with high dosage of lisinopril is not only more effective but also less costly than with low dosage of the drug. The incremental pharmacological costs are offset by savings in hospitalisations costs.
ResearchGate has not been able to resolve any references for this publication.